Clinical trials: Second-Line
HIV, HIV Infections
Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé)
Since the first line antiretroviral (ARV) treatment is now largely accessible in the Sub-Saharian Africa countries, documentation of virological failure, drug resistance patterns and second line treatment evaluation are still to…
- Trial name
- 2LADY (NCT00928187)
- Testing
- emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line), abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line), emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation)
- Where
- 3 sites in Burkina Faso, Cameroon and 1 more
- Volunteers
- 454 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Advanced Gastric or Colorectal Cancer
PD-1-M1-NK Cells in the Treatment of Advanced Gastric or Colorectal Cancer
This is an Early Clinical Study to Investigate the Safety, Pharmacokinetics, and Efficacy of PD-1-M1-NK Cells (YC-T-001) in Patients with Advanced Gastric or Colorectal Cancer Failed or Intolerant to at Least Second-line Therapy.
- Trial name
- NCT07031011
- Testing
- PD-1-M1-NK Cells
- Where
- China
- Volunteers
- 22 people
- Sponsor
- jiuwei cui
Breast Cancer
Benefit of Adding Trastuzumab to Second Line Chemotherapy in Breast Cancer Patients Previously Treated With Trastuzumab
Eligible patients must receive vinorelbine plus capecitabine, with or without trastuzumab, until disease progression or unbearable toxicity.
- Trial name
- NCT00130507
- Testing
- Vinorelbine, Capecitabine, Trastuzumab
- Where
- Spain
- Volunteers
- 14 people
- Sponsor
- Spanish Breast Cancer Research Group
Nonsquamous Non-Small Cell Lung Cancer
A Study of Sintilimab Compared With Docetaxel or Pemetrexed as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer After Failure With Platinum-Containing Chemotherapy
This prospective, single-center, randomized, controlled study will evaluate the efficacy and safety of sintilimab compared with docetaxel or pemetrexed as second-line treatment for patients with stage IV nonsquamous non-small…
- Trial name
- NCT03830411
- Testing
- Sintilimab, Docetaxel, Pemetrexed
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Xin-Hua Xu
Non-small Cell Lung Cancer
To Investigate Efficacy and Safety of Pemetrexed as Second or Third Line Therapy in Patients With Non-small Cell Lung Cancer (NSCLC)
To investigate efficacy and safety of pemetrexed as second or third line therapy in patients with non-small cell lung cancer (NSCLC).
- Trial name
- NCT00191191
- Testing
- Pemetrexed 500 mg/m2, Pemetrexed 1000 mg/m2
- Where
- 16 sites in Japan
- Volunteers
- 226 people
- Sponsor
- Eli Lilly and Company
Advanced Colorectal Cancer
Efficacy Analysis of Cetuximab Plus Irinotecan in Patients With Wild-type KRAS Without Regard to Epidermal Growth Factor Receptor (EGFR) Expressions
The purpose of this study is to investigate the response rate of cetuximab plus irinotecan every 2 weeks in patients harboring wild-type KRAS with and without detectable EGFR-expressing metastatic CRC after failure to irinotecan…
- Trial name
- NCT00637091
- Testing
- Cetuximab, irinotecan
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Asan Medical Center
Breast Cancer, Advanced Breast Cancer
PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)
Hormone Receptor (HR)-positive/Human Epidermal Growth Factor Receptor 2 (HER2)-negative advanced breast cancer (ABC)
- Conditions
- Breast Cancer, Advanced Breast Cancer, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
- Trial name
- PALMIRA (NCT03809988)
- Testing
- Palbociclib, Endocrine therapy
- Where
- 53 sites in France, Germany and 4 more
- Volunteers
- 198 people
- Sponsor
- MedSIR
Advanced Esophageal Squamous Cell Carcinoma
To Evaluate the Efficacy and Safety of Afatinib for Advanced ALTRK-negative ESCC
This is a phase II study to evaluate the effectiveness and safety of Afininib compared to irinotecan in the 3-gene RNA sequencing (ALTRK) negative advanced esophageal squamous squamous carcinoma.
- Trial name
- NCT05818982
- Testing
- Afatinib, Irinotecan
- Where
- 3 sites in China
- Volunteers
- 72 people
- Sponsor
- Peking University
Carcinoma, Small Cell
BI 2536 Second Line Monotherapy in SCLC
Open label, uncontrolled Phase II trial to assess the efficacy and safety of BI 2536 in second line treatment in sensitive-relapse SCLC patients.
- Trial name
- NCT00412880
- Testing
- BI 2536
- Where
- 10 sites in United States, Canada
- Volunteers
- 23 people
- Sponsor
- Boehringer Ingelheim
Cancer, Carcinoma
PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)
To estimate the effect of second-line panitumumab monotherapy on objective response in patients with metastatic or recurrent squamous cell carcinoma of head and neck (SCCHN).
- Conditions
- Cancer, Carcinoma, Head and Neck Cancer, Metastases
- Trial name
- NCT00446446
- Testing
- Panitumumab
- Volunteers
- 52 people
- Sponsor
- Amgen
Metastatic Colorectal Cancer
Post-First Progression Use of Bevacizumab in Metastatic Colorectal Cancer (mCRC)
Bevacizumab beyond progression has been proven to be safe in the community setting (BRiTE) and in the post-marketing study (BEAT), and confirmed its efficacy and safety in the first line with all regimens of chemotherapy.
- Trial name
- SAFE (NCT00862342)
- Testing
- Bevacizumab (Avastin)
- Where
- South Korea
- Volunteers
- 78 people
- Sponsor
- Asan Medical Center
Non-Small Cell Lung Cancer
Docetaxel and Carboplatin Versus Docetaxel as Second Line Treatment in Patients With Non-Small-Cell Lung Carcinoma (NSCLC)
This trial will compare the effectiveness of Docetaxel with or without Carboplatin as second line chemotherapy in patients with Non-Small Cell Lung Cancer, who have not been treated previously with Docetaxel.
- Trial name
- NCT00430651
- Testing
- Docetaxel, Carboplatin
- Where
- 10 sites in Greece
- Volunteers
- 135 people
- Sponsor
- Hellenic Oncology Research Group
Gastric Cancer
Study of S1 Efficacy and Toxicity as Second-line Treatment on Inoperable or Advanced Gastric Cancers
The primary purpose of the study is to investigate the correlation between the efficacy and toxicity of S-1 on gastric cancers and the expression of thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD) and orotate…
- Trial name
- NCT01650766
- Where
- China
- Volunteers
- 80 people
- Sponsor
- The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Colon Cancer, Rectum Cancer
Irinotecan and Cetuximab for Colorectal Cancer as Second Line Therapy
Research Hypothesis: Subjects in the study population who are treated with cetuximab in combination with irinotecan will have higher response rates than subjects treated with irinotecan alone.
- Trial name
- NCT00336856
- Testing
- Cetuximab, Irinotecan
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Pittsburgh
Urothelial Carcinoma
Gemcitabine and Carboplatin After Progression on Enfortumab Vedotin and Pembrolizumab in Advanced/Metastatic Urothelial Carcinoma
The goal of this clinical trial is to learn if a chemotherapy combination called gemcitabine and carboplatin (GC) works to treat advanced urothelial cancer in people who have already been treated with enfortumab vedotin and…
- Trial name
- NCT07043972
- Testing
- Gemcitabine, Carboplatin
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- Fox Chase Cancer Center
Advanced Breast Cancer
Faslodex Advanced Breast Cancer Local Chinese Study
This study will evaluate the efficacy and safety of Faslodex as secondary-line treatment compared with Arimidex in oestrogen receptor positive postmenopausal advanced breast cancer.
- Trial name
- NCT00327769
- Testing
- Fulvestrant, Anastrozole
- Where
- 12 sites in China
- Volunteers
- 234 people
- Sponsor
- AstraZeneca
Gastroesophageal Junction, Gastroesophageal Adenocarcinoma
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
This is a phase 1/2 multicenter, open-label umbrella platform study that will evaluate the safety and efficacy of sacituzumab tirumotecan (MK-2870) plus paclitaxel versus ramucirumab plus paclitaxel, and HER3-DXD plus ramucirumab…
- Conditions
- Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
- Trial name
- NCT06445972
- Testing
- Ramucirumab, Paclitaxel, Sacituzumab Tirumotecan
- Where
- 46 sites in United States, Brazil and 9 more
- Volunteers
- 210 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced NSCLC
Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment
In this study, the investigators provide a combined treatment of personalized tumor neoantigen-based peptide vaccine, PD-1 Inhibitor, and radiotherapy to patients with advanced non-small cell lung cancer (NSCLC) progressed after…
- Trial name
- NCT06751901
- Testing
- Radiotherapy, PD-1 inhibitor, Neoantigen-based peptide vaccine
- Where
- 2 sites in China
- Volunteers
- 10 people
- Sponsor
- The First Affiliated Hospital of Nanchang University
Advanced Non-Small Cell Lung Cancer
Pemetrexed +/- Carboplatin as Second Line Treatment in NSCLC
The aim of this study is to compare time to progression between the combination pemetrexed-carboplatin and pemetrexed alone in previously treated patients with locally advanced or metastatic NSCLC.
- Trial name
- NCT00786331
- Testing
- Pemetrexed, Pemetrexed plus carboplatin
- Where
- 21 sites in Italy
- Volunteers
- 230 people
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
Ovarian Cancer
Masitinib in Combination With Gemcitabine in Advanced/Metastatic Epithelial Ovarian Cancer Patients
The objective is to evaluate the efficacy and safety of masitinib in combination with gemcitabine in refractory ovarian cancer patients.
- Trial name
- NCT02490488
- Testing
- Masitinib, Gemcitabine
- Where
- 6 sites in Algeria, France and 4 more
- Volunteers
- 248 people
- Sponsor
- AB Science
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.